Saratov JOURNAL of Medical and Scientific Research

Assessment of efficiency of application of various analogues of insulin in treatment of diabetes type 2

Year: 2014, volume 10 Issue: №3 Pages: 461-464
Heading: Endocrinology Article type: Original article
Authors: Rodionova T.l., Orlova M.M.
Organization: Saratov State Medical University

Purpose: to estimate efficiency of treatment of analogues of insulin Glargin and insulin Detemir in patients with diabetes type 2. Material and methods. 147 patients with diabetes type 2 which have been initially receiving combined therapy by oral antihyperglycemic agent and NPH-insulin have been under the study. Level of glycated hemoglobin has been defined in 3 and 6 months for the general assessment of control of aglycemia. Results. According to the study the use of insulin analogues (Detemir, Glargin) versus NPH insulin for 6 months allowed to reach individual target values of glycemia in 70% of patients with diabetes type 2 with a low risk of hypoglycemia. Conclusion. The use in clinical practice of modern insulin analogues and simple algorithm for dose titration, allows simulating as closely as possible the physiological insulin secretion, helping to achieve compensation of carbohydrate metabolism in larger numbers of patients in comparison with NPH insulin.

I.American Diabetes Association: standards of medical care in diabetes. Diabetes Care 2014; 37 (Suppl. 1): 5-13
2. Gerstein H., Yusuf S., Riddle M.C., et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155 (1): 26-32
3. Riddle M., Umpierrez G., Digenio A., et al. Challenging the "Monnier concept": high basal (not postprandial) glucose dominates hyperglycemic exposure over a wide range of A1С on oral therapy, and contributes significantly even after addition of basal insulin [abstract]. Diabetes 2010; 59 (Suppl 1): 626
4. Manini R., Forlani G., Moscatiello S., et al. Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes, nutr metab cardiovasc dis 2007; 17 (7): 493-8
5. Specialized diabetes care / ed. by II Dedov, MV Shestakova. 6th edition. Moscow, 2013; 120 p.
6. Rosenstock J., Dailey G., Massi-Benedetti M., et al. Reduced hypoglycemia risk with insulin glargine: a metaanalysis comparing insulin glargine with human NPH in type 2 diabetes. Diabetes Care 2005; 28: 950-55
7. Chatterjee S., Jarvis-Kay J., Rengarajan T., et al. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes: the glargine and aspart study (GLASS): A randomized cross-over study. Diabetes Res Clin Pract 2007; 77: 215-222
8. Davies M., Storms F., Shutler S., et al. LANTUS study group Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288
9. Kennedy L., Herman W.H., Strange P., et al. GOALA1С Team Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 2006; 29: 1-8
10. Kacerovsky-Bielesz G, Dressier A, Freunscht R. Long-term glycemic control with insulin glargine in type 2 diabetes. Diabetes Res Clin Pract 2006; 71: 184-191.

2014_03_461-464.pdf410.18 KB

No votes yet